The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies.
Adult
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antirheumatic Agents
/ administration & dosage
Arthritis, Rheumatoid
/ drug therapy
Biological Therapy
/ methods
Cross-Sectional Studies
Female
Humans
Male
Middle Aged
Morocco
Registries
Retrospective Studies
Rituximab
/ administration & dosage
Tumor Necrosis Factor-alpha
/ antagonists & inhibitors
Rituximab
rheumatoid arthritis
tocilizumab
treatment
tumor necrosis factor inhibitors
Journal
The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
11
2020
accepted:
05
02
2021
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
26
5
2021
Statut:
epublish
Résumé
the aim of our study is to determine, from data of the Moroccan register of biotherapies, the factors influencing the choice of the first prescribed biological treatment. cross-sectional multicenter study including rheumatoid arthritis patients who were initiated the first biological treatment either: Rituximab, an anti-TNF, or Tocilizumab. The determinants related to the patient and disease have been gathered. A univariate and then multivariate analysis to determine the factors associated with the choice of the first bDMARDs was realized. a total of 225 rheumatoid arthritis patients were included in the Moroccan registry. The mean age was 52 ± 11 years, with female predominance 88% (n = 197). The first prescribed biological treatment was Rituximab 74% (n = 166), the second one was Tocilizumab, 13.6% (n = 31) then comes the anti-TNF in 3 our study suggests that Rituximab and TNFi are associated with the type of insurance and Tocilizumab is the most prescribed biologic mono-therapy in RA patients. Further studies are needed to confirm these results.
Identifiants
pubmed: 33995789
doi: 10.11604/pamj.2021.38.183.27081
pii: PAMJ-38-183
pmc: PMC8106777
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antirheumatic Agents
0
Tumor Necrosis Factor-alpha
0
Rituximab
4F4X42SYQ6
tocilizumab
I031V2H011
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
183Informations de copyright
Copyright: Meryem Eddaoudi et al.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Rev Bras Reumatol. 2013 Feb;53(1):57-65
pubmed: 23588516
N Engl J Med. 2011 Dec 8;365(23):2205-19
pubmed: 22150039
Rheumatol Ther. 2015 Dec;2(2):165-172
pubmed: 27747537
Drugs Aging. 2016 Feb;33(2):97-107
pubmed: 26833350
Lancet. 2016 Oct 22;388(10055):2023-2038
pubmed: 27156434
Ann Rheum Dis. 2010 Jan;69(1):88-96
pubmed: 19297346
Rheumatology (Oxford). 2009 Aug;48(8):906-10
pubmed: 19478038
Clin Rheumatol. 2017 Apr;36(4):753-761
pubmed: 28058538
Autoimmun Rev. 2017 Dec;16(12):1185-1195
pubmed: 29037899
Ann Rheum Dis. 2014 Jan;73(1):86-94
pubmed: 23962455
Ann Rheum Dis. 2014 Mar;73(3):492-509
pubmed: 24161836
Z Rheumatol. 2017 Apr;76(3):210-218
pubmed: 27518855
Ann Rheum Dis. 2016 Jan;75(1):3-15
pubmed: 25969430
J Clin Rheumatol. 2014 Sep;20(6):301-5
pubmed: 25160011
BMJ Open. 2012 Nov 12;2(6):
pubmed: 23148339
Lancet. 2013 May 4;381(9877):1541-50
pubmed: 23515142
Ann Rheum Dis. 2018 May;77(5):650-657
pubmed: 29237621
Ann Rheum Dis. 2016 Jul;75(7):1336-42
pubmed: 26374404
Future Sci OA. 2018 Dec 04;5(1):FSO355
pubmed: 30652022
Semin Arthritis Rheum. 2016 Apr;45(5):519-32
pubmed: 26607440
J Manag Care Spec Pharm. 2015 May;21(5):409-23
pubmed: 25943002